ASCO 2022 | Pembrolizumab, emavusterib + radiosurgery: a novel trimodal therapy for metastatic melanoma

Bently Doonan, MD, University of Florida, Gainesville, FL, talks on a up and coming clinical trial involving a novel trimodal therapy of pembrolizumab and emavusertib (CA-4948) with radiosurgery to optimize treatment for metastatic melanoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.